192 Results
Sort By:
Published on May 14, 2024
Research led by the Icahn School of Medicine at Mount Sinai, New York, has confirmed a link between the genetics of inflammatory bowel disease (IBD) and Parkinson’s disease. The team that discovered the connection hopes their findings can help design therapies that could target both conditions. “Our research not only…
Published on April 15, 2024
A single fecal microbiota transplant (FMT) induced mild, but long-lasting beneficial effects on motor symptoms in patients with early-stage Parkinson’s disease (PD) in a small clinical study by Belgian researchers. About 20 people received the treatment, and their motor score improved by a mean of 5.8 points over a year. …
Published on March 21, 2024
Neurologists at Beth Israel Deaconess Medical Center (BIDMC) in Boston have developed a skin biopsy test able to assist in the early diagnosis of Parkinson’s disease and related neurodegenerative disorders, collectively known as synucleinopathies. The study, published in the Journal of the American Medical Association (JAMA), highlights the effectiveness of…
Published on February 8, 2024
A fluorescent coumarin-based, two-sensor array correctly discriminates between four different amyloids implicated in amyloid-related pathologies with 100 percent classification, according to research from an Australian team. Their work was published in ACS Sensors, and the lead author is Natalie Trinh of the University of Sydney. One of the biggest challenges…
Published on January 23, 2024
The Michael J. Fox Foundation will collaborate with omics-focused Centogene to research and confirm genetic and other omics-related risk factors for Parkinson’s disease. Centogene, which is headquartered in Germany, has a large biodatabank including samples from more than 800,000 people from more than 120 countries. This biobank includes data from…
Published on January 3, 2024
Researchers at the University of Southern California (USC) reported this week they have newly identified a genetic mutation in a small protein that provides significant protection against the development of Parkinson’s disease. This new finding, reported in the journal Molecular Psychiatry, makes this beneficial variant an important target for developing…
Published on November 22, 2023
Merck will acquire neurodegeneration start-up Caraway Therapeutics for a total of up to $610 million, including an undisclosed upfront payment and milestone payments. Caraway specializes in genetically defined neurodegenerative conditions, particularly for Parkinson’s, and rare disease. The biotech is a pioneer in the science of lysosomes—membrane-bound cell organelles that contain…
Published on November 20, 2023
Researchers at the University of Wisconsin-Madison report that they have identified a protein that allows for the production of norepinephrine neurons from stem cells, a development that has significant implications for research in Alzheimer’s disease (AD), Parkinson’s disease and other psychiatric and other neurodegenerative diseases. Stem-cell-derived norepinephrine neurons are found…
Published on November 2, 2023
Using gene therapy to alter circuitry in the brain can improve shaking, stiffness, and other symptoms characteristic of Parkinson’s disease, research in animals shows. Treatment eliminated tremors, restored motor skills, and greatly reduced slowness in movement among primate models with the debilitating neurological disorder. The gene therapy manipulates circuits deep…
Published on October 31, 2023
Researchers at the Barrow Neurological Institute have found that people living in regions that have median levels of air pollution have a 56 percent greater risk of developing Parkinson’s disease compared with those who live in areas with the lowest levels of air pollution. The study, which was conducted to…
Published on October 12, 2023
Signs of Parkinson’s disease can be detected 20-30 years before symptoms appear using a known biomarker, called F-AV-133, and positron emission tomography (PET) scans, according to a new study from researchers at Austin Health and the Florey Institute at the University of Melbourne. This work opens the door to screening…
Published on September 18, 2023
An enzyme biomarker could act as an early warning sign for common neurodegenerative disorders and predict the progression to clinical disease, research suggests. Levels of DOPA decarboxylase (DDC) in cerebrospinal fluid (CSF) and blood plasma were raised in Parkinsonian disorders and dementia with Lewy bodies, which together are called Lewy…
Published on September 13, 2023
AXIM Biotechnologies, a developer of rapid tear drop-based diagnostics, announced today that has successfully developed a tear drop test that is the first rapid, non-invasive, point-of-care diagnostic for Parkinson’s disease (PD). The test detects abnormal alpha-synuclein—an important emerging biomarker of PD—found in a person’s tears. “Our proven expertise in developing…
Published on August 1, 2023
Northwestern Medicine scientists have uncovered a new mechanism by which mutations in the gene parkin contribute to familial forms of Parkinson’s disease. The team used transcriptomics, metabolomics, and super-resolution microscopy, to identify amino acid metabolism as a disrupted pathway in iPSC-derived dopaminergic neurons from patients with parkin-related PD. The discovery, the…
Published on July 10, 2023
U.S. Parkinson’s disease patients being covered by Medicare health insurance are experiencing significant gaps and disparities in their care compared with non-Medicare patients, according to results from a Parkinson’s Foundation and University of Chicago study. As reported in the npj Parkinson’s Disease journal, 90% of U.S. Parkinson’s disease patients are…